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Introduction: Postoperative acute kidney injury (AKI) is a frequently observed complication after on-pump cardiac
surgery (CS) and is associated with adverse patient outcomes. Early identification of patients at risk is essential for
the prevention of AKI after CS. In this study, we analysed whether urinary tissue inhibitor of metalloproteinase 2
(TIMP-2) combined with urine insulin-like growth factor binding protein 7 (IGFBP-7) ([TIMP-2] × [IGFBP-7]) is an
adequate diagnostic test to identify early AKI after on-pump CS.
Methods: In 42 patients undergoing coronary artery bypass graft surgery, we surveyed individual risk factors for AKI
and defined AKI by applying the Kidney Disease: Improving Global Outcomes (KDIGO) classification during the day
of surgery and the following 2 days after surgery. Concentrations of urinary TIMP-2 multiplied by IGFBP-7 were
recorded at four time points: at baseline pre-surgery, at the end of surgery, 4 hours after cardiopulmonary bypass
(CPB) and at 8:00 AM on the first postoperative day.
Results: In total, 38% of the patients experienced AKI. The results showed a median baseline [TIMP-2] × [IGFBP-7]
concentration of 0.3 (ng/ml)2/1,000, decreasing at the end of surgery and then increasing at the next measurement
point 4 hours after CPB and further on the first postoperative day. On the first postoperative day, patients with AKI
had significantly higher concentrations of [TIMP-2] × [IGFBP-7]. On the day of surgery, the concentration did not
significantly differ between patients classified as KDIGO 0 or KDIGO 1 or 2. Previously published cutoff points of
0.3 and 2 were not confirmed in our study cohort.
Conclusion: [TIMP-2] × [IGFBP-7] concentration can be used as a diagnostic test to identify patients at increased risk
of AKI after CS on the first postoperative day. At earlier time points, no significant difference in [TIMP-2] × [IGFBP-7]
concentration was found between patients classified as KDIGO 0 or KDIGO 1 or 2.
Trial registration: German Clinical Trials Register (DRKS) DRKS00005457. Registered 26 November 2013.Introduction
Acute kidney injury (AKI) is one of the most common
organ dysfunctions in critically ill patients [1]. It is fre-
quently observed in patients after cardiac surgery (CS)
involving cardiopulmonary bypass (CPB) [2].
The medical and economic consequences of AKI are
substantial [3]. AKI requiring renal replacement therapy
(RRT) has been reported in 5% of all patients after
CS; 8% to 15% present with increased serum creatinine* Correspondence: omoerer@gwdg.de
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unless otherwise stated.of >1.0 mg/dl; and a discrete increase in creatinine of
25% from baseline is found in 50% [4]. The postope-
rative mortality rate after CPB lies between 2% and 8%,
but it increases exponentially up to 60% in patients
requiring RRT [5,6].
In order to apply preventive and therapeutic measures,
it is essential to estimate the individual risk and severity
of AKI early. Several biomarkers for predicting AKI were
identified during the last decade, but none reached an
acceptable level of suitability or precision [7]. Recently, a
test that quantifies urinary tissue inhibitor of metallo-
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ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Wetz et al. Critical Care  (2015) 19:3 Page 2 of 7factor binding protein 7 (IGFBP-7) has been introduced
[8]. TIMP-2 and IGFBP-7 are involved in G1 cell
cycle arrest of renal tubular cells during the early
period of cell injury caused by ischaemic or inflam-
matory processes which interrupt the integrity and
division of cells with damaged DNA until DNA repair is
accomplished [9-12].
Kashani et al. demonstrated that multiplication of
quantified TIMP-2 and IGFBP-7 results in accurate pre-
diction of AKI risk (area under the receiver operating
characteristic (ROC) curve (AUC), 0.80) [8]. In the same
context, Meersch and colleagues confirmed that urinary
[TIMP-2] × [IGFBP-7] concentration is a sensitive and
specific biomarker to identify AKI following CS [13].
Before broader routine clinical implementation, a thor-
ough analysis of the diagnostic strength of this method
to accurately predict AKI should be repeatedly shown in
clinical trials. Accordingly, the aim of this study was to
clarify the question whether quantification of TIMP-2
and IGFBP-7 is an adequate diagnostic test for detecting
AKI after CS involving CPB.
Material and methods
We included patients admitted to our ICU at the
Department of Anesthesiology and Intensive Care,
University Hospital of Goettingen, Germany, after they
had undergone CS with the use of CPB. The trial was
approved by the local ethics committee of the Medical
University of Goettingen (Ethik-Kommission der Uni-
versitätsmedizin Göttingen; registration number 17/2/
13) and is registered in the German Clinical Trials Register
(DRKS), national trial registration number DRKS00005457,
http://apps.who.int/trialsearch/ (registered 26 November
2013)). It was planned as a substudy of a clinical trial with
the aim of analysing the impact of haemolysis during CPB.
The recruitment period spread from August 2013 to
February 2014. The inclusion criteria were that the patient
had to give informed consent and had to have undergone
(elective or nonelective) coronary artery bypass graft
(CABG) surgery with the use of CPB. The exclusion
criteria were age younger than 18 years, additional si-
multaneous valvular or vascular non–coronary artery
surgery, preexistent chronic renal failure requiring RRT,
CS planned without the use of CPB, heart transplant pa-
tients, preoperative cardiac failure requiring extracorporal
membrane oxygenation, participation in conflicting stud-
ies and refusal to participate in the study.
The following biometrical characteristics, comorbidities
and surgical factors were surveyed: sex, age and body mass
index (BMI), left ventricular ejection fraction (EF), New
York Heart Association congestive heart failure (CHF) clas-
sification, chronic obstructive pulmonary disease (COPD),
insulin-dependent diabetes mellitus (IDDM), use of a
preoperative intra-aortic balloon pump and preoperativeconcentration of serum creatinine. As surgery-related fac-
tors, we reported CABG as primary, redo, elective or emer-
gency surgery; duration of CPB and aortic cross-clamping
(ACC) time; and blood and coagulation products received.
Individual risk stratification was accomplished by deter-
mining the clinical predictive score according to the
method of Thakar and colleagues [6].
Urine measurements were performed at four time
points to evaluate the earliest possible time frame within
an everyday routine clinical setting to diagnose AKI
using a commercially available test (NephroCheck test,
Astute140 Meter; Astute Medical, San Diego, CA, USA).
Measurements were performed at the following time
points:
1. Baseline: before surgery and directly after
induction of anaesthesia and urinary catheterization
2. End of surgery
3. 4 hours after arrest of CPB
4. 8:00 AM on the first postoperative day
(1 day after surgery)
To apply the test, we used several commercially avail-
able supplies (NephroCheck test slide with enclosed test
stripes, buffer solution, test conjugate, quality control
kit, 100-μl pipette). Urine samples were taken from urin-
ary catheter tubes under sterile conditions and processed
immediately after withdrawal. They were stored at room
temperature for a maximum of 2.5 hours before being
processed for testing (according to the manufacturer’s
recommended maximum of 4 hours).
Buffer solution (100 μl) was mixed with 100 μl of the
urine sample and added to the conjugate vial. A quantity
of 100 μl of the mix was applied to the cone of the test
slide and spread on the test stripe. After incubation, an
immunoassay was performed using the Astute140 Meter,
and after 20 minutes the result of the multiplied concen-
tration of the biomarkers ([TIMP-2] × [IDFBP-7]) was
accomplished. Threshold results were displayed as >0.02
and regarded as 0.02 for statistical analyses.
Postoperatively, the definition and graduation of AKI
were determined by applying the Kidney Disease: Impro-
ving Global Outcomes (KDIGO) classification criteria
[14]. Daily KDIGO stage was determined on the basis of
diuresis rate and serum creatinine concentration recorded
on the day of surgery and on the following 2 postoperative
days. We considered the maximum KDIGO stage achieved
by each patient during the postoperative observation
period. Patients were classified as KDIGO 0, 1 or 2. The
cohort was analysed in groups of KDIGO stage 0 and
KDIGO stage >0 with subgroups of KDIGO 1 and
KDIGO 2.
The baseline characteristics of the patients were de-
scribed using median (25th and 75th percentiles) for
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distributed, and number (percentage) for categorical vari-
ables. All analyses were completed with Statistica (Version
10, 1984–2011; StatSoft, Tulsa, OK, USA) and SPSS (IBM
SPSS, Chicago, IL, USA) software and included testing of
distribution with the Kolmogorov-Smirnov test, Mann–
Whitney U test, χ2 test and Fisher’s exact test, as well as
logistic regression. Previously published cutoff points were
evaluated by calculating sensitivity and specificity after ap-
plying them to our patient cohort. ROC analysis was used
to determine optimal cutoff points with combined max-
imized sensitivity and specificity (by Youden index).
Significance testing was two-sided with a significance
level of 0.05. A P-value <0.05 was considered statistically
significant.
Results
Forty-three patients were eligible for the study. One
patient died only few hours after surgery, during the day
of surgery and was excluded from the study. In one pa-
tient, the second and third measurement time points
were identical due to prolonged surgery duration after
CPB termination, so only one urine sample was investi-
gated for that patient.
The study population consisted of 29 men (69%) and
13 women (31%) with a median age of 72 years (inter-
quartile range, 65 to 76) and a mean BMI of 29.6 kg/m2
(Table 1). All but one patient underwent scheduled
elective CABG surgery, and none of the patients had
undergone CS before. The median length of hospital stay
was 12 days. Two patients (4.8%) died postoperatively.Table 1 Baseline characteristics of the study cohorta
All KDIG
Variable n = 42 % Median (IQR) n = 2
Elective surgery 41 97.6 26
EF <35% 4 9.5 1
Preoperative creatinine ≥1.2 mg/dl 26 61.9 8
CHF 18 42.9 14
COPD 14 33.3 10
IDDM 10 23.8 6
Age, yr 72 (65 to 76)
BMI, kg/m2 29.6 (25.7 to 33.1)
CPB time, min 126.5 (100 to 154)
ACC time, min 75.5 (67 to 103)
pRBCs, U 1 (0 to 2)
Hospital LOS, days 12 (3 to 33)
ICU LOS, days 2.5 (1 to 5)
aACC, Aortic cross-clamping; BMI, Body mass index; CHF, Congestive heart failure; C
Left ventricular ejection fraction; ICU, Intensive Care Unit; IDDM, Insulin-dependent dia
statistics are displayed as the distribution of the potential risk factors of acute kidney in
Improving Global Outcomes (KDIGO) stage 0 and KDIGO stage 1 or 2. In the upper row
cohort; in the lower rows, continuous and intraoperative variables are presented as medThe incidence of the preoperative risk factors COPD,
IDDM and EF <35% varied between 10% and 33%.
Serum creatinine ≥1.2 mg/dl was recorded in 40% of the
study cohort (Table 1). According to the Thakar score
risk stratification for postoperative AKI (median, 2;
range 0 to 6), 57% (n = 24) patients were classified as
low-risk (0 to 2 points), 40% (n = 17) as moderate-risk
(3 to 5 points) and 3% (n = 1) had 6 score points and
were thus at high risk (Table 2). Score points were
not significantly higher in the KDIGO 1 or 2 group than
in the KDIGO 0 group.
Univariate analysis of sex, preoperative serum creatinine
level, COPD, IDDM, EF <35%, CHF, elective or nonelec-
tive surgery revealed no significant differences between
patients with versus without AKI.
Median CPB time was 127 minutes, and median ACC-
time was 76 minutes, both of which were longer, but not
significantly so, in the KDIGO 1 or 2 group than in the
KDIGO 0 group. Patients received in median one red
blood cell transfusion; other products were rarely given.
No significant differences in distribution were observed
for univariate analysis of BMI, blood and coagulation
products or length of hospital stay (Table 1). However,
patients in the AKI group were found to be significantly
older (75 years vs. 66.5 years) and to have stayed longer
in the Intensive Care Unit (4.5 days vs. 1 day).
Sixteen patients (38%) experienced AKI within 60 hours
postoperatively, whereas twenty-six patients (62%) had
no AKI. Thirteen patients (31%) were classified as KDIGO
1 and three patients (7%) as KDIGO 2. KDIGO 1 was
achieved due to serum creatinine rise in seven patients,O 0 KDIGO 1 or 2
6 % Median (IQR) n = 16 % Median (IQR) P-value
100 15 93.8 0.38
3.9 3 18.8 0.15
30.8 9 56.3 0.1
53.9 4 25 0.11
38.5 4 25 0.51
23.1 4 25 1
66.5 (61 to 73) 75 (72 to 81) 0.04
30.1 (26.1 to 33.2) 29.1 (25.7 to 33.1) 0.73
115.5 (97 to 147) 134.5 (111 to 176.5) 0.17
70.5 (61–86) 77 (71.5 to 115) 0.12
1 (0 to 2) 0.5 (0 to 3) 0.98
12 (9 to 14) 11.5 (9 to 17.5) 0.58
1 (1 to 4) 4.5 (2.5 to 5.5) 0.02
OPD, Chronic obstructive pulmonary disease; CPB, Cardiopulmonary bypass; EF,
betes mellitus; LOS, Length of stay; pRBCs, Packed red blood cells. Descriptive
jury separately for the total cohort and for the subcohorts of Kidney Disease:
s, categorical preoperative variables are displayed as numbers and ratios of each
ian and interquartile range (IQR, 25th to 75th percentiles), BMI as mean and 95% CI.
Table 2 Distribution of Thakar score pointsa
Thakar scoreb All, N = 42 KDIGO 0, n = 26 KDIGO 1 or 2, n = 16
n % n % n %
0 7 16.7 4 15.4 3 18.8
1 11 26.2 9 34.6 2 12.5
2 6 14.3 4 15.4 2 12.5
3 6 14.3 2 7.7 4 25
4 9 21.4 4 15.4 5 31.3
5 2 4.8 2 7.7 0 0
6 1 2.4 1 4.0 0 0
aKDIGO, Kidney Disease: Improving Global Outcomes. bThakar et al. [6]. In the
absence of risk factors, 0 points are given; a maximum score of 17 points is
possible. The study cohort consisted of patients with 0 to 6 Thakar points,
with most receiving 0 to 4 points. Figure 1 Boxplots grouped by Kidney Disease: improving
global outcomes stage (0 vs. 1 or 2) and time. The measurement
of urinary tissue inhibitor of metalloproteinase 2 (TIMP-2) combined
with urinary insulin-like growth factor binding protein 7 (IGFBP-7)
using the diagnostic test in 42 cardiac surgery patients revealed that
the test was able to discriminate between patients without (dark
grey) acute kidney injury (AKI) and those with (light grey) AKI on the
first postoperative day (area under the receiver operating characteristic
curve, 0.706). The x-axis is measurement time points 1 through
4. The y-axis is the combined concentration of [TIMP-2] × [IGFBP-7]
(ng/ml)2/1,000.
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sified twice on the basis of oliguria, and one patient
showed an increase of serum creatinine (Table 3).
The results of the concentration of ([TIMP-2] ×
[IGFBP-7]) (ng/ml)2/1,000 revealed a baseline median
concentration of 0.3 (ng/ml)2/1,000, decreasing at the
end of surgery to 0.08 (ng/ml)2/1,000 and then increas-
ing at the next measurement point 4 hours after CPB
and further on the first postoperative day.
On the day of surgery, the concentration of ([TIMP-
2] × [IGFBP-7]) (ng/ml)2/1,000 did not significantly differ
between KDIGO 0 and KDIGO 1 or 2. At the first post-
operative day, the median [TIMP-2] × [IGFBP-7] con-
centration of patients without AKI was 0.28 (ng/ml)2/
1,000, whereas patients with AKI had a significantly
higher [TIMP-2] × [IGFBP-7] concentration of 0.79 (ng/
ml)2/1,000 (Figure 1 and Table 4).
Applying previously published cutoff concentrations to
our results (first postoperative day) revealed a sensitivity
of 53% and a specificity of 54% for the cutoff point of
0.3. The cutoff point of 2 led to a sensitivity of 33% and
a specificity of 100% (Table 5).Table 3 Analysis of acute kidney injurya




All 42 100 8 8
KDIGO 0 26 62 – –
KDIGO 1 13 31 7 6
KDIGO 2 3 7 1 2
KDIGO 3 0 0 – –
aThirty-eight percent of the patients had acute kidney injury (AKI), and sixty-two
percent were classified as Kidney Disease: Improving Global Outcomes (KDIGO)
stage 0. Numbers and ratios of patients separated into each KDIGO stage are
displayed. The KDIGO stage was determined on the basis of the creatinine or
diuresis criterion. Eight patients were defined as patients with AKI primarily on
the basis of increased serum creatinine concentration, and eight patients first
reached the threshold of a low diuresis rate.By ROC analysis, we determined optimized cutoff
points of the multiplied biomarker concentration of the
second and last measurement time points. For the base-
line and third (4 hours after CPB) measurement time
points, we found AUCs of 0.451 and 0.512, respectively,
so no cutoff point was built. For the second measure-
ment time point, a cutoff concentration of 0.41 (36%
sensitivity, 92% specificity) was determined and the last
measurement time point defined a cutoff point of 1.065
(47% sensitivity, 96% specificity). The AUCs were 0.634
at the second measurement time point and 0.706 at the
last measurement time point. The diagnostic test was
able to discriminate between patients with and those
without AKI on the first postoperative day (AUC, 0.706;
P = 0.029).
Discussion
In this study, we analysed the precision and discrimi-
native ability of a new set of biomarkers to predict AKI
after CS with CPB. We selected three postoperative
measurement points (end of surgery, 4 hours after the
arrest of CBP and at 8:00 AM on the first postoperative
day) to estimate the earliest possible time frame to pre-
dict or diagnose AKI. On the day of surgery, urinary
[TIMP-2] × [IGFBP-7] concentration did not signifi-
cantly differ between patients with versus those without
AKI. On the first postoperative day, the median concen-
tration of [TIMP-2] × [IGFBP-7] was significantly higher
in patients with AKI. This implies that the diagnostic
Table 4 Characteristics of combined urinary concentration of tissue inhibitor of metalloproteinase 2 combined with
insulin-like growth factor binding protein 7a
All KDIGO 0 KDIGO 1 or 2
Median IQR Median IQR Median IQR P-valueb
Baseline 0.3 0.13 to 0.59 0.33 0.13 to 0.73 0.27 0.12 to 0.525 0.6
End of surgery 0.08 0.03 to 0.28 0.07 0.03 to 0.23 0.07 0.05 to 0.48 0.17
4 hr after CPB 0.17 0.09 to 0.31 0.16 0.09 to 0.3 0.18 0.085 to 0.37 0.91
1 day postoperatively 0.28 0.11 to 0.95 0.28 0.08 to 0.52 0.79 0.15 to 6.56 0.03
aCPB, Cardiopulmonary bypass; IQR, Interquartile range. The median concentrations of urinary tissue inhibitor of metalloproteinase 2 (TIMP-2) combined with urine
insulin-like growth factor binding protein 7 (IGFBP-7) ([TIMP-2] × [IGFBP-7]) (ng/ml)2/1,000 at four measurement time points sorted by Kidney Disease: Improving
Global Outcomes (KDIGO) groups are displayed. [TIMP-2] × [IGFBP-7] concentration first decreased from baseline after surgery and then increased 4 hours after the
arrest of CPB and increased further on the first postoperative day. On the day of surgery (measurement points 1, 2 and 3), no significant difference was found
between patients with acute kidney injury (AKI) (KDIGO 1 or 2) and those without AKI (KDIGO 0). On the first postoperative day, patients with AKI had significantly
higher concentrations of urinary [TIMP-2] × [IGFBP-7]. bP < 0.05 by Mann–Whitney U test was considered statistically significant.
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patients with versus those without AKI on the first
postoperative day, but that it fails to do so on the
day of surgery.
Our results indicate that measurement time points on
the day of surgery were selected too early and could not
predict AKI, because no increase from baseline was
observed and no significant differences were found
between patients with versus those without AKI. We
were not able to identify AKI risk 4 hours after CPB
as Meersch et al. did [13]. The reason for this difference
may lie in different patients and surgical settings, as we
included only patients undergoing CABG surgery and our
study cohort was not limited to high-risk AKI patients.
On the first postoperative day, the test succeeded in AKI
prediction.
Our study presents a new aspect of diagnostic pre-
diction by analysing the concentrations of ([TIMP-2] ×
[IGFBP-7]) (ng/ml)2/1,000 in all patients undergoing
CABG surgery and not only in patients at high risk for
AKI. The fact that we did not focus on only high-risk
patients, but included all patients undergoing CABG
surgery, is reflected in the absence of risk factors for
AKI (established according to the scoring method of
Thakar et al. [6]) in 16.7% of the study cohort. The pre-
viously published trials included only patients with at
least one defined risk factor [8] or patients with 6 or
more Thakar points. In contrast, our study included onlyTable 5 Analysis of applying previously published cutoff
points
Cutoff Sensitivity Specificity
End of surgery 0.3 0.36 0.84
2 0.07 0.96
1 day after surgery 0.3 0.53 0.54
2 0.33 1
The sensitivity and specificity of applied previously published cutoff points of
0.3 and 2 are shown. The highest sensitivity was found at the cutoff point of
0.3 on the first postoperative day; the highest specificity was found with a
cutoff point of 2 on the first postoperative day.43% of patients with more than 2 Thakar points, but
57% of patients had ≤2 points. Because an AKI incidence
of 38% still can be found in patients with 0 to 4 Thakar
points, we considered it important to determine whether
the diagnostic test is also applicable in this lower risk
cohort.
Compared to surgical procedures with valve or com-
bined surgery, CABG-only surgery requires shorter CBP
and ACC time, assuming lesser injury to the kidneys. So,
it is possible that the AKI of lesser severity reached in
our patient population was due to different surgical
conditions and not of a time frame within which the
biomarker concentration rises to a significant level at early
measurement time points. The risk of injury to the kid-
neys could have been considerably higher in the trial of
Meersch and colleagues [13] than in our present study,
because they also included patients undergoing valvular
and combined surgeries with assumed higher risks of kid-
ney injury due to longer CBP and ACC times than we ob-
served in our patient population (140 and 98 minutes vs.
127 and 78 minutes, respectively). This may have led to
the divergent results and may be a reason why the trials of
Kashani et al. [8] and Meersch et al. [13], who included
only patients at higher risk for AKI, showed more precise
results of the biomarker test.
Because the test was not perfectly applicable to our
patients of mainly low-grade kidney injury (KDIGO 1)
and Kashani et al. proved good results on KDIGO 2 and
3, the question arose wheather the biomarker test might
be better applicable for predicting high-grade kidney in-
jury [8].
Previously published cutoff points of 0.3 and 2 [8]
could not be confirmed in our study cohort. Applying
the low cutoff point resulted in a sensitivity of 53% and
a specificity of 54%. The cutoff point of 2 led to a sensi-
tivity of 33% and a specificity of 100%. In contrast, in
our present study, we found a cutoff point of 1.1 with an
AUC of 0.71 (46.67% sensitivity, 96.15% specificity). The
reason for this finding may lie again in different patient
cohort composition and different surgical settings, as
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to weaker results.
Another difference between the studies can be found
in the trend of [TIMP-2] × [IGFBP-7] concentration. We
observed higher baseline concentrations, with decreasing
trends for the following measurement points. This finding
does not correspond to the results of the earlier trials.
This may be attributable to a different fluid management
concept at our department during CS that relies mainly
on crystalloid solutions instead of colloids, as well as a low
rate of transfusion during CABG surgery.
AKI was determined on the basis of the KDIGO classifi-
cation system, which provides an objective, comparable,
precise definition of AKI and corresponds to current
standards [14]. Clinical tools used to detect AKI, such as
serum creatinine rise and measurement of urine output,
are well established and easy to determine in routine
clinical practice. Nevertheless, they can be influenced by
various unspecific factors, such as muscle mass and
volume status, and do not reflect glomerular filtration or
the degree of tubular injury [15-17].
An adequate test would confirm a diagnosis in a timely
manner with high discrimination and precision; would
be superior to, or at least complement, established clinical
markers; and would lead to improvement of therapeutic
management and patient outcome. The introduced com-
mercial NephroCheck test of combined urinary TIMP-2
and IGFBP-7 concentrations, which are involved in cell
cycle pathways of renal tubular cells [9-12], is easy to per-
form with a small urine sample; the results are displayed
after 20 minutes.
The question whether this diagnostic test is adequate
to predict AKI after CS can be answered affirmatively
with a trend towards moderate sensitivity and specificity
on the first postoperative day. Not only accurate prog-
nostic stratification but also early diagnosis of AKI are
essential for optimal medical management [18]. Clinical
markers of kidney function often fail to detect AKI at a
time when interventions may provide benefit [8]. The
observed clinical markers, known for their delayed reac-
tion, increased in 62.5% of patients until the first post-
operative day and in 37.5% on the second postoperative
day. Because the combined [TIMP-2] × [IGFBP-7] con-
centration performed poorly on the day of surgery and
started to discriminate between patients with and those
without AKI risk not prior to, but on, the first postopera-
tive day, the advantage in earlier identification of AKI risk
over clinical markers and the value for early anticipation
of the immediate risk of AKI [19] remain to be elucidated.
Our results raise the question whether the biomarker
product stratifies AKI more precisely than KDIGO criteria
do, and therefore the benefit of comparison might be lim-
ited. Thus, the severity of AKI might differ between two
patient cohorts when both are clinically classified asKDIGO stage 1 or 2, a difference that may be identified
and stratified only by biomarkers. Biomarkers may then
lead to an expansion of diagnostic criteria for AKI by
allowing detection of patients with a subclinical risk of
kidney injury when routine diagnostic tools such as serum
creatinine and urine output stay unchanged [20,21]. Fur-
thermore, testing of biomarkers sheds light on the individ-
ual pathogenesis of AKI [8], enabling differential diagnosis
in critically ill patients.
However, the value of successfully predicting AKI at this
time point needs further assessment. After investigations
into how biomarkers would be utilized by clinicians
and into the form of application in clinical practice
[20], further trials are needed to clarify the question
whether the use of biomarkers leads to consequences
in therapeutic management or improvement in clinical
outcomes, as recently proposed, by early assessment of
prognosis, advanced warning and alerting clinicians [19].Conclusion
On the basis of our findings in 42 patients undergoing
CABG surgery, we conclude that the recently introduced
[TIMP-2] × [IGFBP-7] concentration–based NephroCheck
test allows identification of patients at increased AKI risk
after CS starting at the first postoperative day, but not
during the early postoperative phase. We assume that
quantification of [TIMP-2] × [IGFBP-7] concentration may
be more suitable in patients undergoing CABG surgery
who are at high risk for AKI and may be less precise
in patients at low risk for AKI.Key messages
 The [TIMP-2] × [IGFBP-7]–based NephroCheck test
allowed us to identify patients at increased AKI risk
after CS.
 Significant changes of [TIMP-2] × [IGFBP-7] started
on the first postoperative day.
 During the early postoperative phase, no significant
difference was found between patients with versus
those without AKI.
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